Pacira | PCRX - Cost Of Sales

Stock Price
21.00
Daily Change
0.64 3.14%
Monthly
-19.23%
Yearly
-19.54%
Q1 Forecast
19.91

Pacira reported $48.6M in Cost of Sales for its fiscal quarter ending in September of 2025.





Cost Of Sales Change Date
Astellas Pharma JPY 149.13B 10.88B Dec/2025
Bristol-Myers Squibb USD 4.92B 657M Dec/2025
Ironwood Pharmaceuticals USD 29.83M 560K Sep/2024
J&J USD 7.97B 689M Dec/2025
Ligand Pharmaceuticals USD 11.9M 733K Sep/2025
Novo Nordisk DKK 15.15B 2.3B Dec/2025
Pacira USD 48.6M 6.59M Sep/2025
Perrigo USD 666.2M 27.2M Sep/2025
Pfizer USD 6.29B 2.12B Dec/2025
Supernus Pharmaceuticals USD 43.29M 5.64M Sep/2025
Teva Pharmaceutical Industries USD 2.06B 120M Dec/2025
Xeris Pharmaceuticals USD 13.71M 1.81M Sep/2025
Zoetis USD 683M 3M Sep/2025